As the U.S. stock market surges on news of a trade deal with the UK, investors are keenly observing how such developments might influence various sectors, including smaller-cap stocks. Penny stocks, often associated with smaller or newer companies, continue to offer intriguing opportunities for growth at lower price points despite being considered a somewhat outdated term. By focusing on strong financials and solid fundamentals, these under-the-radar investments can present compelling prospects for those looking to explore beyond the mainstream market options.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Safe Bulkers (NYSE:SB) | $3.39 | $358.57M | ✅ 4 ⚠️ 3 View Analysis > |
| Tuya (NYSE:TUYA) | $2.29 | $1.39B | ✅ 3 ⚠️ 3 View Analysis > |
| Smith Micro Software (NasdaqCM:SMSI) | $1.045 | $16.42M | ✅ 4 ⚠️ 4 View Analysis > |
| Kiora Pharmaceuticals (NasdaqCM:KPRX) | $3.35 | $9.9M | ✅ 4 ⚠️ 1 View Analysis > |
| Flexible Solutions International (NYSEAM:FSI) | $3.60 | $45.28M | ✅ 4 ⚠️ 2 View Analysis > |
| Imperial Petroleum (NasdaqCM:IMPP) | $2.63 | $89.65M | ✅ 3 ⚠️ 2 View Analysis > |
| Heritage Global (NasdaqCM:HGBL) | $1.975 | $70.64M | ✅ 3 ⚠️ 2 View Analysis > |
| BAB (OTCPK:BABB) | $0.84 | $6.12M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (NasdaqGS:LCUT) | $3.29 | $72.4M | ✅ 3 ⚠️ 2 View Analysis > |
| CBAK Energy Technology (NasdaqCM:CBAT) | $0.843 | $74.37M | ✅ 4 ⚠️ 1 View Analysis > |
Click here to see the full list of 767 stocks from our US Penny Stocks screener.
We'll examine a selection from our screener results.
Alpha Tau Medical (NasdaqCM:DRTS)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company specializing in the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for treating solid cancer, with a market cap of $182.29 million.
Operations: Alpha Tau Medical Ltd. currently has no reported revenue segments as it focuses on developing its diffusing alpha-emitters radiation therapy for solid cancer treatment.
Market Cap: $182.29M
Alpha Tau Medical Ltd. is a pre-revenue company focusing on its innovative Alpha DaRT technology for cancer treatment, recently receiving FDA approval to initiate a pilot study for recurrent glioblastoma. Despite no revenue, the company maintains financial stability with short-term assets of US$64.2 million surpassing liabilities and sufficient cash runway for over two years. The recent follow-on equity offering raised US$36.86 million, potentially bolstering its development efforts but increasing share dilution risk. Though unprofitable with rising losses, the seasoned management team provides experienced leadership in navigating these challenges as they advance clinical trials and product development.
- Navigate through the intricacies of Alpha Tau Medical with our comprehensive balance sheet health report here.
- Evaluate Alpha Tau Medical's prospects by accessing our earnings growth report.
Mynd.ai (NYSEAM:MYND)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Mynd.ai, Inc. operates in the technology sector by offering interactive flat panel display products and has a market capitalization of $33.21 million.
Operations: The company generates revenue from its eLMTree segment, amounting to $267.38 million.
Market Cap: $33.21M
Mynd.ai, Inc., with a market cap of US$33.21 million, operates in the technology sector but faces challenges typical of penny stocks. The company reported a significant revenue drop to US$267.38 million from the previous year and experienced increased net losses to US$95.72 million. Despite this, Mynd.ai maintains more cash than debt and covers both short- and long-term liabilities with its assets. Recent executive changes see Arthur Giterman stepping in as CEO after Vin Riera's departure, potentially impacting strategic direction as Giterman continues his dual role as CFO amidst high share price volatility and recent buybacks totaling 204,888 shares for US$0.44 million.
- Unlock comprehensive insights into our analysis of Mynd.ai stock in this financial health report.
- Assess Mynd.ai's previous results with our detailed historical performance reports.
Granite Point Mortgage Trust (NYSE:GPMT)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Granite Point Mortgage Trust Inc. is a real estate investment trust that focuses on originating, investing in, and managing senior floating-rate commercial mortgage loans and other debt-related commercial real estate investments in the United States, with a market cap of approximately $91.97 million.
Operations: Granite Point Mortgage Trust Inc. does not report distinct revenue segments, focusing instead on its core activities within the United States.
Market Cap: $91.97M
Granite Point Mortgage Trust Inc., with a market cap of approximately US$91.97 million, operates in the mortgage REIT sector but remains unprofitable, reporting a net loss of US$7.02 million for Q1 2025, an improvement from the previous year's substantial losses. Despite its financial challenges and high debt levels, Granite Point maintains sufficient short-term assets to cover liabilities and has reduced its debt-to-equity ratio over five years. The company declared dividends on both common and preferred stocks but struggles with earnings coverage. Revenue forecasts indicate significant growth potential despite ongoing profitability issues, reflecting typical volatility associated with penny stocks.
- Click to explore a detailed breakdown of our findings in Granite Point Mortgage Trust's financial health report.
- Explore Granite Point Mortgage Trust's analyst forecasts in our growth report.
Turning Ideas Into Actions
- Navigate through the entire inventory of 767 US Penny Stocks here.
- Want To Explore Some Alternatives? Rare earth metals are the new gold rush. Find out which 23 stocks are leading the charge.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Mynd.ai might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com